cagrilintide injection (10 mg) For Research Cagrilintide

General statements about broad compatibility of any diluent with investigational peptides are not supported by authoritative evidence and should not be relied upon

Observed Side Effects (From Clinical Trials) In the Lancet 2021 Phase 2 trial (n=706), at the highest 4.5 mg/week dose, 88% of participants reported at least one side effect and 63% reported a GI-specific event

C., & Nindl, B

A new gastric juice peptide, BPC, heals both acute and chronic gastrointestinal lesions. Journal of Physiology (Paris), 95(1-6), 7992

It comes as a freeze-dried powder, called a lyophilized powder, that a lab dissolves before any study